An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Conditions: Multiple Sclerosis (MS) Interventions: Drug: Avonex (IFN β-1-a, Biogen Netherlands B.V); Drug: Rebif (IFNβ-1-a, Merck Europe B.V.); Drug: Extavia (IFNβ-1-b, Novartis Europharm Limited); Drug: Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG); Drug: Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V); Drug: MS disease modifying drugs (MSDMDs) Sponsors: Bayer; Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Conditions: Recurrent B Acute Lymphoblastic Leukemia; Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory B-Cell Non-Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma Interventions: Biological: Interferon Beta-1A; Procedure: X-Ray Imaging; Procedure: Echocardiography; Procedure: Multigated Acquisition Scan; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Procedure: Lumbar Puncture; Procedure: Bone Marrow Aspira tion; Procedure: Bone Marrow Bi...
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials
The Impact of Interferon Beta 1a on Egyptian Relapse-Reemitting Multiple Sclerosis Patients
Condition: Multiple Sclerosis Intervention: Other: Blood sample collection Sponsor: German University in Cairo Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2023 Category: Research Source Type: clinical trials
